GRPR and prostate carcinoma: The gastrin-releasing peptide receptor (GRPR) has been also intensively explored as a target both for imaging [51,52,53,54,55,56,57,58,59] or radionuclide therapy [41,60,61,62,63,64,65] of prostate cancer and other GRPR-expressing cancers.